MedKoo product information:

 MRX-1024

D-methionine formulation MRX-1024 is a proprietary oral formulation of D-methionine with antioxidant and antimucositis activities. D-methionine formulation MRX-1024 may selectively protect the oral mucosa from the toxic effects of chemotherapy and radiation therapy without compromising antitumor activity. D-methionine may be converted into the L- isomer in vivo, particlualry in instances of L-methionine deprivation; both isomers have antioxidant activity which may be due, in part, to their sulfur moieties and chelating properties. L-methionine, an essential amino acid, also may help to maintain the ratio of reduced glutathione to oxidized glutathione in cells undergoing oxidative stress and may provide a source of L-cysteine for glutathione synthesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer:    Molecular Therapeutics.

1: Hamstra DA, Eisbruch A, Naidu MU, Ramana GV, Sunkara P, Campbell KC, Ross BD, Rehemtulla A. Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients  treated with radiation therapy with or without cisplatinum for head and neck cancer. Clin Cancer Res. 2010 May 1;16(9):2666-76. Epub 2010 Apr 13. PubMed PMID: 20388849.